Aim 1:  Compare the molecular phenotypes of BLC and BRCA1-mutant breast cancers.

Aim 2:  Identify specific functional defects in DNA repair in BLC using DNA repair assays in viable tumor cells obtained from clinical samples.

Aim 3:  Access the response of a cohort of ER(-), PR (-), HER2 (-) breast cancers to cis-platinum in a phase II neo-adjuvant trial and determine if results of informative assays developed above correlate with clinical response.

Key Personnel:

David M. Livingston, MD – DFCI

Daniel P. Silver, MD, PhD – DFCI

Judy E. Garber, MD, MPH – DFCI

Andrea Richardson, MD, PhD – BWH

Paula D. Ryan, MD, PhD – MGH

Zhigang (Charles) Wang, PhD – BWH

J. Dirk Iglehart, MD - DFCI

Recent Publications:

Garber JE, Richardson A, Harris LN, Miron A, Silver D, Golshan M, Ryan PD, Ganesan S, Li X, Wang ZC, Clarke K, Tung N, Iglehart JD, Winer EP.  Neoadjuvant Cis-Platin® (CDDP) in Triple-Negative Breast Cancer (BC). 29th Annual San Antonio Breast Cancer Symposium, 2006.

Wang ZC, Silver DM, Chang SB, Lu X, Kim JY, Richardson AL, Iglehart JD. Distinct patterns of chromosomal alterations characterize the subtypes of breast cancer, implying different mechanisms of chromosomal instability and support a new function of BRCA1 in tumor suppression. (Manuscript in preparation) 

Michaela J. Kandel, Rebecca Gelman, Zsofia K. Stadler, Anthony Martyniak, Serena Masciari, Laura Collins, Andrea L. Richardson, Lyndsay N. Harris, Alexander Miron, Stuart Schnitt, Judy E. Garber.  Prevalence of BRCA1 Mutations in Triple Negative Breast Cancer (Manuscript submitted, J Clin Oncol)

• 
• 
• 
  • Breast
    • Projects
    • Cores
    • Developmental Research
    • Calendar
    • Scientific Advances
    • Symposia/Events
    • Helpful Links
  • Gastrointestinal Cancers
  • Kidney
  • Lung
  • Myeloma
  • Ovarian
  • Prostate
  • Skin
• 
• 
• 
•